Axsome Therapeutics (NASDAQ:AXSM) Raised to “Strong-Buy” at Wolfe Research

Axsome Therapeutics (NASDAQ:AXSM) was upgraded by equities research analysts at Wolfe Research to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

AXSM has been the subject of a number of other research reports. Needham & Company LLC reissued a “buy” rating and set a $225.00 price target on shares of Axsome Therapeutics in a research report on Monday. Robert W. Baird set a $209.00 price target on Axsome Therapeutics in a research note on Tuesday, January 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Axsome Therapeutics in a report on Wednesday, January 14th. Oppenheimer restated an “outperform” rating and set a $220.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, December 31st. Finally, UBS Group lifted their price objective on shares of Axsome Therapeutics from $248.00 to $251.00 and gave the stock a “buy” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $216.12.

Axsome Therapeutics Stock Down 2.8%

Shares of NASDAQ AXSM opened at $169.95 on Monday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. Axsome Therapeutics has a 1 year low of $86.99 and a 1 year high of $191.50. The stock’s 50-day simple moving average is $174.91 and its 200-day simple moving average is $145.40. The firm has a market cap of $8.57 billion, a price-to-earnings ratio of -46.06, a PEG ratio of 12.57 and a beta of 0.40.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 251.47% and a negative net margin of 28.69%.The firm had revenue of $196.00 million during the quarter, compared to the consensus estimate of $191.33 million. The business’s quarterly revenue was up 65.0% compared to the same quarter last year. As a group, equities analysts anticipate that Axsome Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Herriot Tabuteau sold 32,410 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $185.60, for a total value of $6,015,296.00. Following the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at $1,341,702.40. This trade represents a 81.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Nick Pizzie sold 12,000 shares of Axsome Therapeutics stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $187.92, for a total value of $2,255,040.00. Following the sale, the chief financial officer directly owned 42,588 shares in the company, valued at $8,003,136.96. The trade was a 21.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 308,874 shares of company stock valued at $51,390,805. 22.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Axsome Therapeutics by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after acquiring an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in shares of Axsome Therapeutics by 2,407.9% in the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after purchasing an additional 7,320 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Axsome Therapeutics by 38.7% during the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock valued at $35,189,000 after purchasing an additional 84,151 shares during the last quarter. Caxton Associates LLP acquired a new stake in Axsome Therapeutics during the first quarter valued at approximately $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Axsome Therapeutics by 29.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after buying an additional 17,250 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors.

Key Stories Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Revenue and commercial strength — Q4 sales jumped roughly 65% year‑over‑year and full‑year 2025 revenue rose strongly, led by Auvelity and Sunosi, beating consensus revenue estimates and showing solid commercial traction. AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
• Positive Sentiment: Pipeline progress — Axsome dosed the first patient in the CLARITY Phase 3 trial of solriamfetol for MDD with excessive daytime sleepiness, adding a near‑term clinical catalyst. Axsome Therapeutics Initiates CLARITY Phase 3 Trial
• Positive Sentiment: Analyst support — Needham reaffirmed a Buy and set a $225 price target, signaling continued bull case and upside potential. Benzinga coverage of Needham rating
• Neutral Sentiment: Earnings materials and call — Management released the Q4 / FY2025 results, slide deck and earnings call transcript; these provide detail behind the revenue beat and guidance/comments for investors to review. Axsome press release / slide deck
• Neutral Sentiment: Mixed EPS reporting — several outlets summarized Q4 results and call highlights (transcript and summaries available), useful for investors but containing varying EPS figures across reports. AXSM Q4 2025 Earnings Call Highlights
• Negative Sentiment: Profitability and accounting headlines — despite revenue strength, Axsome remains loss‑making (negative net margins and a large negative ROE); some reports flagged a wider per‑share loss in certain metrics, creating near‑term investor concern. Axsome Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Valuation and pipeline skepticism — some analysts and commentators argue the pipeline may be overvalued and commercial uptake risks remain, tempering enthusiasm despite upside price targets. Axsome: Q4 Earnings Review — Pipeline May Be Overvalued

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.